Numis Securities upgraded shares of Udg Healthcare (LON:UDG) to a hold rating in a research note released on Thursday, ThisIsMoney.Co.Uk reports.
Several other analysts have also recently weighed in on UDG. Barclays raised Udg Healthcare to an overweight rating and dropped their price objective for the stock from GBX 770 ($10.06) to GBX 720 ($9.41) in a report on Thursday, April 4th. Peel Hunt reissued a buy rating on shares of Udg Healthcare in a report on Tuesday, January 29th. Finally, Liberum Capital reissued a buy rating on shares of Udg Healthcare in a report on Tuesday, January 29th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of GBX 780.57 ($10.20).
Shares of LON:UDG opened at GBX 667 ($8.72) on Thursday. The stock has a market cap of $1.66 billion and a price-to-earnings ratio of 444.67. Udg Healthcare has a 1-year low of GBX 545 ($7.12) and a 1-year high of GBX 950.50 ($12.42). The company has a debt-to-equity ratio of 27.53, a current ratio of 2.02 and a quick ratio of 1.80.
Udg Healthcare Company Profile
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates in two segments, Ashfield and Sharp. The Ashfield segment offers commercialization services for the pharmaceutical and healthcare industry in the areas of advisory, communications, and commercial and clinical services.
Recommended Story: Should You Consider an Index Fund?
Receive News & Ratings for Udg Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Udg Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.